Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 9, 2016
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5GyGerard Morton, Hans T Chung, Merrylee McGuffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2018
Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysisJoelle Helou, Isabelle Thibault, William Chu, et al.
Medical Physics|October 27, 2023
Deep learning-based ultrasound auto-segmentation of the prostate with brachytherapy implanted needlesPrakash Hampole, Thomas Harding, Derek Gillies, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 15, 2024
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year updateJohn M Hudson, Andrew Loblaw, Merrylee McGuffin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 29, 2018
Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trialsYasir Alayed, Patrick Cheung, Geordi Pang, et al.
International Journal of Radiation Oncology, Biology, Physics|July 30, 2022
The Impact of Disease Progression on Health-Related Quality of Life Outcomes in Patients With Oligometastatic Disease at 12 Months Post Stereotactic Body Radiation TherapyAisling S Barry, Andrea Bezjak, Joelle Helou, et al.
Brachytherapy|December 22, 2022
Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancerNoelia Sanmamed, Lisa Joseph, Juanita Crook, et al.
Cancers|June 22, 2023
Clinical Outcomes of Patients with Metastatic Breast Cancer Treated with Hypo-Fractionated Liver RadiotherapyMelinda Mushonga, Joelle Helou, Jessica Weiss, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2021
Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy BoostHima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 5, 2021
Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of lifeHima Bindu Musunuru, Patrick Cheung, Danny Vesprini, et al.
Pageof 7